Literature DB >> 33068931

Haloperidol in palliative care: Indications and risks.

Iwona Zaporowska-Stachowiak1, Katarzyna Stachowiak-Szymczak2, Mary-Tiffany Oduah3, Maciej Sopata4.   

Abstract

Individual response to medication depends on several factors (age, gender, body weight, general clinical condition, genetics, diet, hydration status, comorbidities, co-administered drugs and their mode of administration, smoking, alcohol overuse, environmental factors, e.g. sunlight) that may contribute to adverse drug reactions even at therapeutic doses. Patients in palliative care are at increased risk of these reactions. Unwanted drug effects diminish the quality of life and may lead to a suboptimal dying process. Haloperidol is one of the three most commonly used drugs in palliative care and the most commonly employed typical antipsychotic. It has also been recommended for inclusion into the palliative care emergency kit of home care teams. As such, it is important to be fully conversant with the indications, benefits, and risks of haloperidol, especially in the context of palliative care.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Adverse effect; Cardiotoxicity; Haloperidol; Neurotoxicity; Palliative care

Mesh:

Substances:

Year:  2020        PMID: 33068931     DOI: 10.1016/j.biopha.2020.110772

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan.

Authors:  Moawia Mohammed Ali Elhassan; Amal Abdulbagi Abdulfatah Mohammed; Amnah Abdulazeem Omer; Arafa Ahmed Mohammed Azeem; Hiba Mohammed Abdelkfi Mohammed; Isra Elameen Mustafa Ibrahim; Nashwa Abdelaziz Abdelrheem Ahmed
Journal:  Ecancermedicalscience       Date:  2022-03-24

2.  Haloperidol Instigates Endometrial Carcinogenesis and Cancer Progression by the NF-κB/CSF-1 Signaling Cascade.

Authors:  Jung-Ying Chiang; Fu-Ju Lei; Huan-Jui Chang; Sung-Tai Wei; Chi-Chung Wang; Yen-Chih Huang; Hwai-Lee Wang; Chi-Fen Chuang; Shu-Yu Hu; Chia-Hung Hsieh
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 3.  Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis.

Authors:  Shakti Shrestha; Arjun Poudel; Magnolia Cardona; Kathryn J Steadman; Lisa M Nissen
Journal:  Ther Adv Drug Saf       Date:  2021-10-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.